Norgine launches Mugard for oral mucositis in Spain

Mugard is a medical device for the prevention and management of the signs and symptoms of oral mucositis caused by chemotherapy and radiation therapy.

Mugard is a mucoadhesive oral rinse proven to prevent and manage the lesions and symptoms of oral mucositis by adhering to the mucosal surface of the mouth and forming a soothing, protective layer. Approximately 20-40% of patients receiving conventional chemotherapy and nearly all patients receiving head and neck radiation therapy suffer from oral mucositis. With limited effective treatment options available, Mugard has been created for patients to take prior to and during cancer treatment to relieve the signs and symptoms of oral mucositis.

Peter Martin, Chief Operating Officer, Norgine said: "We are delighted to launch Mugard in Spain as it provides cancer patients with an important treatment for oral mucositis, when we know there are limited effective treatment options available. Managing the side effects of cancer treatment is essential to keeping patients on their cancer therapy."

Norgine holds the rights to Mugard in Europe, Australia and New Zealand. Norgine anticipates further launches of Mugard in 2016 and 2017.